Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Shah Highlights Immunotherapy for Esophageal Cancer

July 19th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

FDA Grants Atezolizumab Combo Breakthrough Designation for Frontline HCC

July 18th 2018

The FDA has granted atezolizumab a breakthrough therapy designation for use in combination with bevacizumab as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.

Evolving Global Treatment Landscape for Gastric Cancer

July 18th 2018

Novel Targeted Approaches in Gastroesophageal Cancer

July 18th 2018

Checkpoint Inhibitors: Emerging Role in GE Cancer

July 18th 2018

Shortfalls in Recent Gastroesophageal Clinical Trials

July 18th 2018

PD-1 Inhibitors for Advanced Gastroesophageal Cancer

July 18th 2018

RAINBOW Study: Antiangiogenic Therapy in Gastric Cancer

July 18th 2018

Second-line Treatment for Recurrent or Progressive GEC

July 18th 2018

Guidelines for Metastatic Frontline Therapy in GEC

July 18th 2018

Improving Surgical Outcomes for Gastroesophageal Cancer

July 18th 2018

FLOT Regimen for Resectable Gastroesophageal Cancer

July 18th 2018

Next-Generation Sequencing for Gastric and GEJ Cancer

July 18th 2018

Gastroesophageal Cancer: Initial Approaches

July 18th 2018

Global Trends in Gastroesophageal Cancer

July 18th 2018

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

July 17th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Dr. Yezefski Compares Costs and Outcomes of Chemotherapy in the US and Canada

July 16th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, compares the costs and outcomes of chemotherapy in the United States and Canada for patients with colorectal cancer.

Dr. Choti on Updates in Neoadjuvant and Adjuvant Therapy for CRC

July 13th 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses updates in neoadjuvant and adjuvant therapy for patients with colorectal cancer.

FDA Grants Pembrolizumab Priority Review for HCC

July 12th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced hepatocellular carcinoma